BioSpace News Archive

Heart Test Laboratories, Inc.d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the first patient has been dosed in a Phase 1/2 study of NUV-1511, the Company’s first DDC to enter the clinic.

IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024.

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported financial and operating results for the quarter and year ended December 31, 2023 and provides its 2024 outlook.

Global Liver Institute recognizes the importance of the first approval by the U.S. Food and Drug Administration of a medication for nonalcoholic steatosis.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today released positive topline clinical data from its Phase 3 pivotal pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film and findings from the FDA Type C meeting.

Today, the Food and Drug Administration (FDA) granted accelerated approval of a first of its kind drug therapy, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH) in patients who have progressed to fibrosis.

Movano Health (Nasdaq: MOVE) has completed another hypoxia trial with the University of California, San Francisco (UCSF) yielding new blood oxygen saturation (SpO2) data, confirming the accuracy of its Evie Ring pulse oximeter exceeds the U.S. Food and Drug Administration (FDA) guidelines.

Biotheus Inc. and Hansoh Pharmaceutical Group Co., Ltd., China’s leading innovation-driven pharmaceutical company, jointly announced that the two parties will further expand their strategic collaboration, following their current partnership since 2022.

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi®.